Targeting CDCA3 Enhances Sensitivity to Platinum-Based Chemotherapy in Non-Small Cell Lung Cancer

被引：0
|
作者：
Adams, M. [1 ]
Burgess, J. [1 ]
Richard, D. [1 ]
O'Byrne, K. [2 ]
机构：
[1] Inst Hlth & Biomed Innovat, Translat Res Inst, Woolloongabba, Qld, Australia
[2] Inst Hlth & Biomed Innovat, Translat Res Inst, Brisbane, Qld, Australia
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期
关键词：
non-small cell lung cancer; prognostic factor; cisplatin chemotherapy;
D O I：
10.1016/j.jtho.2017.09.468
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MA 03.11
引用
收藏
页码：S1810 / S1811
页数：2
相关论文
共 50 条
  • [1] CDCA3 is a Novel Prognostic Cell Cycle Protein and Target for Therapy in Non-Small Cell Lung Cancer
    Adams, Mark
    Burgess, Joshua
    Gately, Kathy
    Snell, Cameron
    Richard, Derek
    O'Byrne, Kenneth
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S837 - S837
  • [2] Contribution of genetic factors to platinum-based chemotherapy sensitivity and prognosis of non-small cell lung cancer
    Perez-Ramirez, Cristina
    Canadas-Garre, Marisa
    Angel Molina, Miguel
    Robles, Ana I.
    Jose Faus-Dader, Maria
    Angel Calleja-Hernandez, Miguel
    MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH, 2017, 771 : 32 - 58
  • [3] Expression of CDCA3 Is a Prognostic Biomarker and Potential Therapeutic Target in Non-Small Cell Lung Cancer
    Adams, Mark N.
    Burgess, Joshua T.
    He, Yaowu
    Gately, Kathy
    Snell, Cameron
    Zhang, Shu-Dong
    Hooper, John D.
    Richard, Derek J.
    O'Byrne, Kenneth J.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (07) : 1071 - 1084
  • [4] Effect of platinum-based chemotherapy for non-small cell lung cancer patients with interstitial lung disease
    Hirotsugu Kenmotsu
    Tateaki Naito
    Keita Mori
    Ryo Ko
    Akira Ono
    Kazushige Wakuda
    Hisao Imai
    Tetsuhiko Taira
    Haruyasu Murakami
    Masahiro Endo
    Toshiaki Takahashi
    Cancer Chemotherapy and Pharmacology, 2015, 75 : 521 - 526
  • [5] Effect of platinum-based chemotherapy for non-small cell lung cancer patients with interstitial lung disease
    Kenmotsu, Hirotsugu
    Naito, Tateaki
    Mori, Keita
    Ko, Ryo
    Ono, Akira
    Wakuda, Kazushige
    Imai, Hisao
    Taira, Tetsuhiko
    Murakami, Haruyasu
    Endo, Masahiro
    Takahashi, Toshiaki
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 75 (03) : 521 - 526
  • [6] Genetic polymorphisms as potential pharmacogenetic biomarkers for platinum-based chemotherapy in non-small cell lung cancer
    Sito, Hilary
    Tan, Shing Cheng
    MOLECULAR BIOLOGY REPORTS, 2024, 51 (01)
  • [7] Paclitaxel/platinum-based perioperative chemotherapy and surgery in stage IIIA non-small cell lung cancer
    Choi, IS
    Oh, DY
    Kwon, JH
    Kim, SI
    Park, SR
    Bak, JY
    Kim, JH
    Kim, DW
    Kim, YT
    Kim, TY
    You, CK
    Kim, YW
    Heo, DS
    Bang, YJ
    Sung, SW
    Park, CI
    Kim, NK
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2005, 35 (01) : 6 - 12
  • [8] Meta-analysis of P53 expression and sensitivity to platinum-based chemotherapy in patients with non-small cell lung cancer
    Lin, Sheng
    Li, Xiaoqin
    Lin, Ming
    Yue, WenXiang
    MEDICINE, 2021, 100 (05) : E24194
  • [9] Cellular immunotherapy combined with platinum-based chemotherapy prolongs survival for non-small cell lung cancer patients
    Qian, Lei
    Ding, Xiao
    Li, Fang-Qi
    Tian, Hui-Min
    Chen, Xiao
    Han, Fu-Jun
    Wang, Hong-Yi
    Li, Wen-Qian
    Niu, Chao
    Xu, Jian-Ting
    Li, Zhao-Zhi
    He, Hua
    Cui, Jiu-Wei
    NEOPLASMA, 2023, 70 (02) : 251 - 259
  • [10] Prognostic implications of survivin and lung resistance protein in advanced non-small cell lung cancer treated with platinum-based chemotherapy
    Huang, Wenheng
    Mao, Yan
    Zhan, Yongzi
    Huang, Jianheng
    Wang, Xiangping
    Luo, Penghui
    Li, Li
    Mo, Dunchang
    Liu, Qiong
    Xu, Huimin
    Huang, Changjie
    ONCOLOGY LETTERS, 2016, 11 (01) : 723 - 730
12345